Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2694790 | 0.78 | LMNA (0.43) | GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL28207929 | 0.77 | GABRA1 (0.39) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL7229461 | 0.76 | GABRA1 (0.47) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL28199640 | 0.67 | GABRA1 (0.32) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL3899496 | 0.65 | CA1 (0.35) | GABRA1GABRB2CA1CA2 | |
| SCHEMBL3887814 | 0.65 | CA1 (0.35) | GABRA1GABRB2CA1CA2 | |
| SCHEMBL3890193 | 0.65 | CA1 (0.35) | GABRA1GABRB2CA1CA2 | |
| SCHEMBL8649694 | 0.65 | LMNA (0.37) | — | |
| SCHEMBL61153 | 0.64 | LMNA (0.33) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL28324731 | 0.62 | PTGS1 (0.42) | GABRA1GABRB2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684863-B1 | IODOARENE DERIVATIVE, METHOD FOR PRODUCING OPTICALLY ACTIVE SPIROLACTONE COMPOUND USING SAME, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLIZATION ADDUCT | NAT UNIV CORP NAGOYA UNIV (JP) | 2017-05-24 | — | — | EP | disclosed |
| US-9000216-B2 | Iodoarene derivative, method for manufacturing optically active spirolactone compound by using the same, and method for manufacturing optically active cycloadduct | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2015-04-07 | — | — | US | disclosed |
| EP-2684863-A1 | IODOARENE DERIVATIVE, METHOD FOR PRODUCING OPTICALLY ACTIVE SPIROLACTONE COMPOUND USING SAME, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLIZATION ADDUCT | National University Corporation Nagoya University (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130338364-A1 | IODOARENE DERIVATIVE, METHOD FOR MANUFACTURING OPTICALLY ACTIVE SPIROLACTONE COMPOUND BY USING THE SAME, AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CYCLOADDUCT | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2013-12-19 | — | — | US | disclosed |
| CN-103415501-A | Iodoarene derivative, method for producing optically active spirolactone compound using same, and method for producing optically active cyclization adduct | UNIV NAGOYA NAT UNIV CORP | 2013-11-27 | — | — | CN | disclosed |
| US-7381746-B2 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20060142388-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338364-A1 | IODOARENE DERIVATIVE, METHOD FOR MANUFACTURING OPTICALLY ACTIVE SPIROLACTONE COMPOUND BY USING THE SAME, AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CYCLOADDUCT | ADRA1A, HIRA, REN | GABRA1 435/4885GABRB2 1201/4885FABP3 279/4885 |
| US-20060142388-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative | GRIA3, GRIN3A, GRM3 | GABRA1 67/4885GABRB2 75/4885FABP3 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.